Inventiva SA
NASDAQ:IVA
Intrinsic Value
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. [ Read More ]
The intrinsic value of one IVA stock under the Base Case scenario is 2.58 USD. Compared to the current market price of 3.16 USD, Inventiva SA is Overvalued by 18%.
Valuation Backtest
Inventiva SA
Run backtest to discover the historical profit from buying and selling IVA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Inventiva SA
Current Assets | 48.2m |
Cash & Short-Term Investments | 26.9m |
Receivables | 16.2m |
Other Current Assets | 5.1m |
Non-Current Assets | 21.4m |
PP&E | 9.1m |
Intangibles | 541k |
Other Non-Current Assets | 11.7m |
Current Liabilities | 50.2m |
Accounts Payable | 37.7m |
Accrued Liabilities | 3.6m |
Other Current Liabilities | 8.9m |
Non-Current Liabilities | 51.4m |
Long-Term Debt | 32.2m |
Other Non-Current Liabilities | 19.3m |
Earnings Waterfall
Inventiva SA
Revenue
|
17.5m
EUR
|
Operating Expenses
|
-120.1m
EUR
|
Operating Income
|
-102.7m
EUR
|
Other Expenses
|
-7.8m
EUR
|
Net Income
|
-110.4m
EUR
|
Free Cash Flow Analysis
Inventiva SA
IVA Profitability Score
Profitability Due Diligence
Inventiva SA's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Inventiva SA's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
IVA Solvency Score
Solvency Due Diligence
Inventiva SA's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Inventiva SA's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IVA Price Targets Summary
Inventiva SA
According to Wall Street analysts, the average 1-year price target for IVA is 12.22 USD with a low forecast of 6.61 USD and a high forecast of 16.72 USD.
Shareholder Return
IVA Price
Inventiva SA
Average Annual Return | 48.63% |
Standard Deviation of Annual Returns | 111.5% |
Max Drawdown | -87% |
Market Capitalization | 158.4m EUR |
Shares Outstanding | 52 371 085 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Contact
IPO
Employees
Officers
The intrinsic value of one IVA stock under the Base Case scenario is 2.58 USD.
Compared to the current market price of 3.16 USD, Inventiva SA is Overvalued by 18%.